Publishing of Orion Corporation's Interim Report for January-September 2016 on 25 October 2016
(Thomson Reuters ONE) -
ORION CORPORATION STOCK EXCHANGE RELEASE 11 OCTOBER 2016 at 9:00 A.M. EEST
Publishing of Orion Corporation's Interim Report for January-September 2016 on
25 October 2016
Orion will publish its Interim Report for January-September 2016 on Tuesday, 25
October 2016 approximately at 12:00 noon Finnish time (EEST). The release and
related presentation material in Finnish and in English will be available on the
Group's homepage at www.orion.fi/en/investors promptly after the publishing.
News conference for analysts and media
A news conference for analysts and media will be held on Tuesday, 25 October
2016 at 13:30 EEST at Hotel Kämp, address Pohjoisesplanadi 29, Helsinki.
President and CEO Timo Lappalainen will give a brief presentation in English on
the financial review. Questions can be asked after the result presentation.
Participants should be prepared to present a photo ID on request.
Live webcast and conference call
A link to the live webcast will be available at Orion's website
www.orion.fi/en/investors.
The conference call ID is 3897800 and the phone numbers to participate the
conference are:
Finland: +358 (0)9 7479 0404
Sweden: +46 (0)8 5065 3942
UK: +44 (0)20 7026 5967
USA: +1 719-325-2202
News conference recordings
A recording of the event in English and a recording of the presentation by the
President and CEO in Finnish will be available on the Orion website later the
same day.
Silent period
The silent period preceding the publication is ongoing and continues until the
disclosure.
Orion Corporation
Timo Lappalainen Jari Karlson
President and CEO CFO
Contact person:
Tuukka Hirvonen, Communications Manager, IR & Financial Communications
tel. +358 10 426 2721
Publisher:
Orion Corporation
www.orion.fi/en
Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. The core therapy areas of Orion's pharmaceutical R&D are
central nervous system (CNS) disorders, oncology and respiratory for which Orion
developes inhaled Easyhaler® pulmonary drugs.
Orion's net sales in 2015 amounted to EUR 1,016 million and the company had
about 3,400 employees. Orion's A and B shares are listed on Nasdaq Helsinki.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Orion Oyj via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 11.10.2016 - 08:01 Uhr
Sprache: Deutsch
News-ID 499672
Anzahl Zeichen: 3304
contact information:
Town:
Espoo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 200 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Publishing of Orion Corporation's Interim Report for January-September 2016 on 25 October 2016"
steht unter der journalistisch-redaktionellen Verantwortung von
Orion Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
